<DOC>
	<DOCNO>NCT02215876</DOCNO>
	<brief_summary>This phase II , single institutional study , evaluate novel neo-adjuvant regimen patient operable , HER2-negative , breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Doxorubicin/Cyclophosphamide Followed Eribulin Chemotherapy ( ACE ) Operable HER2-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Signed Written Informed Consent 2 . Target Population 1 . Histologically confirm primary invasive adenocarcinoma breast . 2 . Patients operable , T24 , N03 , M0 , T1N1 breast cancer ( stage IIA , IIB , IIIA , IIIB IIIC ) minimum tumor size 2 cm 3 . Tumors must HER2/neu expression negative , determine local hospital laboratory ( IHC ≤ 2+ FISH negative ) . 4 . No prior treatment ( irradiation , chemotherapy , hormonal , immunotherapy investigational , etc . ) breast cancer exclude therapy DCIS . Subjects receive hormone replacement therapy ( HRT ) eligible therapy discontinue least 2 week start study therapy . 5 . Subjects receive radiotherapy DCIS may enroll . 6 . Disease free prior malignancy ≥ 5 year exception curatively treat basal cell carcinoma skin carcinoma situ cervix . 7 . ECOG PS 0 1 . 8 . Accessible treatment followup . 9 . Baseline cardiac echocardiogram scan LVEF ≥ 50 % . 10 . Adequate recovery recent surgery . At least one week must elapse minor surgery ( placement venous access device fine needle aspiration ) least 4 week major surgery . 3 . Laboratory Parameters 1 . Absolute neutrophil count ( ANC ) ≥ 1500/mm3 2 . Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) . 3 . AST ALT ≤ 2.5 time upper limit normal ( ULN ) . 4 . Platelets ≥ 100,000/ mm3 . 5 . Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance &gt; 60 mL/min ( measure calculate CockcroftGault method ) . 6 . Normal PTT either INR PT &lt; 1.5 x ULN . 4 . Age Sex Women , least 21 year age . ) Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 8 week last dose chemotherapy manner risk pregnancy minimize . WOCBP include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( define amenorrhea ≥ 12 consecutive month ; woman hormone replacement therapy [ HRT ] document serum follicle stimulate hormone [ FSH ] level &gt; 35 mIU/mL ) . Even woman use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence whose partner sterile ( vasectomy ) consider childbearing potential . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour first dose investigational product . 1 . Sex Reproductive Status 1 . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 8 week last dose chemotherapy . 2 . Women pregnant ( include positive pregnancy test enrollment prior study drug administration ) breastfeeding . 2 . Target Disease Exceptions 1 . Evidence metastatic breast cancer follow standard tumor stag workup . 2 . Evidence inflammatory breast cancer . 3 . Evidence baseline sensory motor neuropathy . 3 . Medical History Concurrent Diseases 1 . Known human immunodeficiency viral ( HIV ) infection . 2 . Serious intercurrent infection nonmalignant medical illness uncontrolled control may jeopardize therapy . 3 . Psychiatric disorder condition render subject incapable complying requirement protocol . 4 . Clinically significant history cardiovascular disease ( history unstable angina , congestive heart failure , uncontrolled hypertension , myocardial infarction valvular heart disease ) . 5 . Subjects unfit breast and/or axillary surgery ( complete fixation tumor , skin infiltration , erythema breast , and/or ulceration ) . 6 . Current participation another drug trial . 7 . Subjects receive prior anthracycline therapy . 8 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical illness ( e.g. , infectious disease ) must enrol study . Eligibility criterion study carefully consider ensure safety study subject ensure result study use . It imperative subject fully meet eligibility criterion . 4 . Allergies Adverse Drug Reactions ) Known allergy study drug 5 . Prohibited Therapies and/or Medications ) Other concurrent antitumor , chemotherapy , hormonal therapy , immunotherapy regimen radiation therapy , standard investigational .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Her 2-negative breast cancer</keyword>
	<keyword>neoadjuvant doxorubicin/cyclophosphamide follow Eribulin chemotherapy</keyword>
</DOC>